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We provide in this paper a detailed characterization of the human
peripheral CD4þ CD127lowCD25þ regulatory T cell (Treg) compart-
ment, with a particular emphasis in deﬁning the population
expressing higher levels of the IL-6 receptor (IL-6R). We provide a
description of the phenotype of this population by assessing both the
surface expression by ﬂow cytometry as well as their transcriptional
proﬁle and functional features. In addition, we also present functional
data describing the responsiveness of these subsets to IL-6 signalling
in vitro and to IL-2 in vivo. The data presented in this paper support
the research article “Human IL-6RhiTIGIT CD4þCD127lowCD25þ T













R.C. Ferreira et al. / Data in Brief 12 (2017) 676–691 677proﬁle” (Ferreira RC et al., 2017; doi: 10.1016/j.clim.2017.03.002) [1].
& 2017 The Authors. Published by Elsevier Inc. This is an open access
article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Speciﬁcations Tableubject area Biology
ore speciﬁc
subject areaHuman Immunologyype of data Tables (x3) and Figures (x12)
ow data was
acquiredFlow cytometry (Fortessa; BD biosciences); Gene expression proﬁling (NanoString
Technologies)ata format Analyzed ﬂow cytometry ﬁles and normalized gene expression counts (from
Nanostring)xperimental
factorsFlow cytometry and gene expression proﬁling was performed in freshly isolated
PBMCs or CD4þ T cells. Cytokine production was assessed following in vitro sti-
mulation with PMA þ ionomycin. Cell proliferation was assessed by ﬂow cyto-
metry by culturing cells in vitro with anti-CD3/anti-CD28 stimulation.xperimental
featuresDelineation of the Treg compartment was performed in human peripheral blood
cells using polychromatic ﬂow cytometry. The global transcriptional proﬁle of the
assessed T cell subsets was assessed in sorted cells isolated ex vivo.ata source
locationSamples from human volunteers and T1D patients were collected in Cambridge,
UK.ata accessibility All primary non-clinical data are available in this article. The DILT1D data from
individuals prior to normalization as a group are available, however they cannot
be anonymized sufﬁciently to be able to put into the public domain without risk of
participant identiﬁcation. Data are available on request, through the Cambridge
University institutional repository (DOI link: https://doi.org/10.17863/CAM.832).elated research
articleThe data presented in this paper support the research article “Human IL-
6RhiTIGIT CD4þCD127lowCD25þ T cells display potent in vitro suppressive
capacity and a distinct Th17 proﬁle” (Ferreira RC et al., 2017) [1].Value of the data
 Data provide a detailed description of the human peripheral Treg compartment at both the protein
and transcriptional level.
 The ﬂow cytometry data provides a valuable resource for other researchers to compare the
expression levels of a number of classical Treg surface markers within the deﬁned CD4þ T cell
populations deﬁned here.
 The detailed information on the ﬂow cytometry antibodies and polychromatic panel combinations
will be a valuable tool for researchers in the ﬁeld to help design their speciﬁc immunostaining
panels.
 Cell subset heterogeneity is one of the main challenges in the description of human Treg popu-
lations, and is clearly highlighted in the data presented in this paper.
 Data provide precise quantitative information regarding the expression levels of a broad range of
immune genes at the mRNA level in highly puriﬁed human Treg subsets both ex vivo and after
in vitro stimulation.
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The dataset contained in this article provides a detailed characterization of the expression of the
IL-6 receptor (IL-6R) on circulating human CD4þ CD127lowCD25high T cells ex vivo. These data also
provide a functional characterization of the assessed T cell subsets, with a particular emphasis on a
subset of IL-6Rhi regulatory T cells (Tregs) lacking the expression of the co-inhibitory receptor TIGIT.
The Fig. 1 and Fig. 2 depict the delineation of the assessed immune subsets and their responsiveness
to IL-6 signalling. Fig. 3 depicts data from a clinical study investigating the responsiveness of the
assessed T cells subsets to IL-2 signalling in vivo. Fig. 4 depicts the proliferative capacity of the Treg
subsets in vitro, in the absence of exogenous IL-2. Fig. 5 and Fig. 6 depict the expression at the protein
level of Th17 surface markers. Fig. 7 depicts the differential mRNA expression of 579 immune genes
between IL-6RhiTIGIT and IL-6RhiTIGITþ Tregs. Fig. 8, Fig. 9 and Fig. 10 depict the immunopheno-
typing of the Th17 transcription factor RORγt, and different tissue-homing receptors at the protein
level. Fig. 11 depicts the expression of two cytokines, IL-17 and IL-10, in TIGITþ Tregs and Fig. 12
depicts the variation of HELIOS-TIGIT- and HELIOSþTIGITþ Tregs measured by intracellular ﬂow
cytometry on cryopreserved peripheral blood mononuclear cells (PBMCs) on 8 selected patients from
the DILT1D clinical study. Table 1 provides the complete information on the ﬂuorochrome-conjugated
antibody panels used in tis study, and Table 2 and Table 3 contain the complete gene expression dataFig. 1. Gating strategy for the delineation of IL-6Rhi CD127lowCD25þ T cells (Tregs). (A) Gating strategy for the delineation of IL-6Rlo
and IL-6Rhi CD127lowCD25þ Tregs, deﬁned as the lower and upper 20th percentile, respectively, of the IL-6R mean ﬂuorescence
intensity (MFI) distribution in total CD127lowCD25þ Tregs. (B) Histograms depict the distribution of IL-6R expression and the
respective frequency of IL-6Rlo and IL-6Rhi cells among: (i) CD45RAþ naïve (depicted in blue); (ii) total (depicted in black); and (iii)
CD45RA memory (depicted in red) CD127lowCD25þ Tregs. Frequencies shown in the ﬁgure represent the average frequency of the
IL-6Rlo and IL-6Rhi cells in the three assessed Treg subsets from 33 healthy donors. (C) Data shown depict the expression of TIGIT
versus IL-6R in one illustrative donor and the frequency (GeoMean þ/ 95% CI) of IL-6Rhi cells in the TIGITþ (depicted in green)
and TIGIT (depicted in red) subsets of CD127lowCD25þCD45RA mTregs in 33 healthy donors. P value was calculated using a two-
tailed paired non-parametric Wilcoxon signed rank test, comparing the frequency of IL-6Rhi cells in the TIGITþ and TIGIT subsets.
(D) Histograms illustrate the distribution of the two sorting markers TIGIT and IL-6R following ﬂow-cytometric sorting.
Fig. 2. Memory Tregs are sensitive to IL-6 signalling in vitro. (A) Gating strategy for the delineation of the CD45RA memory T
effector (Teff) and Treg subsets. (B) Frequency of pSTAT3þ cells following stimulation of freshly isolated PBMCs with 0, 1 or 10
ng/ml of IL-6. Intracellular levels of pSTAT3 were measured by ﬂow cytometry in CD4þ memory Teffs (depicted in black) and in
CD4þ memory Tregs (depicted in red) from three healthy volunteers. (C) Histograms depict the distribution of the pSTAT3
mean ﬂuorescence intensity (MFI) in memory Teffs (top panel) and memory Tregs (bottom panel) in response to stimulation
with 0, 1 or 10 ng/ml of IL-6 in one illustrative donor.
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in vitro stimulation, respectively.2. Experimental design, materials and methods
2.1. Patient selection
Patient selection and the protocol for the “Adaptive study of IL-2dose on regulatory T cells in type
1 diabetes” (DILT1D) has been published previously [2,3]. A subset of 22 T1D patients (median age ¼
26, range 18–48) were selected for this study, and assessed for the expression of IL-6R on Tregs. A
blood sample was taken before treatment to establish baseline Treg frequencies and phenotypes,
followed by subcutaneous administration of a single dose of recombinant human IL-2 (Proleukin/
aldesleukin; dose range 45,000–737,000 IU/m2) on day 0. The patients were bled 90 min after
treatment, and then daily to day 4 and at days 7, 9, 14, 21 and 60.
Study participants for all further immunophenotyping and functional assays included in this study were
adult healthy volunteers recruited from the Cambridge BioResource (http://www.cambridgebioresource.
Fig. 3. Effect of single-dose IL-2 treatment on the expression of IL-6R on the CD4þ T cell compartment in vivo. (A,B) Data
shown depict the variation (Mean þ/ SEM) of the frequency of IL-6Rhi cells on: (i) CD127þCD25 CD45RA Teffs (A);
and (ii) IL-6Rhi CD127þCD25 CD45RAþ naïve T cells (B) compared to the pre-treatment baseline, following IL-2
treatment in 22 T1D patients enrolled in the “Adaptive study of IL-2 dose on regulatory T cells in type 1 diabetes” (DILT1D)
[2,3]. Median pre-treatment baseline frequencies of IL-6Rhi cells were 39.3% (range: 21.5–59.9%) and 5.39% (range: 1.49–
30.4%) within CD4þ CD45RA Teffs and CD4þ CD45RAþ naïve T cells, respectively. (C) Data shown depict the variation
(Mean þ/ SEM) of the IL-6R mean ﬂuorescence intensity (MFI) levels on the surface of total CD127lowCD25þ Tregs
compared to the pre-treatment baseline MFI levels (median ¼ 600; range: 392–836). Patients were stratiﬁed based on
whether they received: (i) the lower IL-2 doses of 0.04–0.045 x 106 U/ml (N ¼ 8; depicted in black); or (ii) the higher IL-
2 doses of 0.16–0.737106 U/ml (N ¼ 14; depicted in red). The MFI cuttoff to deﬁne IL-6Rhi cells was the same as the one
used for the Treg subset (detailed in Fig. 1). The maximum increases over the baseline pre-treatment frequencies
achieved during the course of the study are indicated for each IL-2 dosing group. P values for the maximum increase in
the frequency of the assessed parameter in response to a single dose of IL-2 was calculated using a two-tailed paired
non-parametric Wilcoxon signed rank test comparing the frequencies observed at the timepoint where the maximal
increase was achieved with the respective baseline pre-treatment frequencies. P values for the IL-2 dose-dependent
effects were calculated using a two-tailed non-parametric a two-tailed non-parametric Mann-Whitney test comparing
the frequency of IL-6Rhi cells between the low and high dose groups at each timepoint. The DILT1D data from individuals
prior to normalization as a group are available, however they cannot be anonymized sufﬁciently to be able to put into the
public domain without risk of participant identiﬁcation. Data are available on request, through the Cambridge University
institutional repository (DOI link: https://doi.org/10.17863/CAM.832). *P o 0.05; **P o 0.01; ns ¼ not signiﬁcant.
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written informed consent was obtained from the participants.2.2. Flow cytometry
Treg immunophenotyping in healthy donors was performed in fresh peripheral blood mono-
nuclear cells (PBMCs) isolated by Ficoll gradient centrifugation (Lymphoprep; STEMCELL
Fig. 4. Proliferative capacity of IL-6RhiTIGIT mTregs is dependent on exogenous IL-2. Proliferative capacity of sorted (i) IL-
6RhiTIGITþ (depicted in green), (ii) IL-6RhiTIGIT (depicted in red), (iii) IL-6RloTIGITþ (depicted in blue) mTregs, and (iv)
CD127þCD25CD45RA Teff cells (depicted in black) was assessed in response to in vitro stimulation with anti-CD3/CD28
beads, in the absence of exogenous IL-2. Data (mean þ/ SEM) were obtained from cells sorted from three independent
donors. Proliferation and suppressive capacity were calculated using the Division Index in FlowJo, setting 0% suppression as the
condition with the respective Teffs cultured in the absence of Tregs.
Fig. 5. CD161 and CCR6 expression is increased on IL-6RhiTIGIT mTregs. (A,B) Frequency (GeoMean þ/ 95% CI) of CD161 (N
¼ 23) (A) and CCR6 (N ¼ 12) (B) was assessed by ﬂow cytometry in freshly isolated PBMCs from healthy donors. Data were
stratiﬁed according to the three assessed mTreg subsets: IL-6Rlo (depicted in blue), IL-6RhiTIGITþ (depicted in green) and
IL-6RhiTIGIT (depicted in red). P values were calculated using a two-tailed paired non-parametric Wilcoxon signed rank test.
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conjugated antibodies against surface receptors (see Table 1 for details) for 45 min at 4 °C. Fixation
and permeabilisation was performed using FOXP3 Fix/Perm Buffer Set (BioLegend) and cells were
then stained with the respective intracellular antibodies for 45 min at room temperature (Table 1).
For the DILT1D clinical trial participants, 30 ml whole blood were collected into lithium heparin
tubes and processed within 4 h of phlebotomy. Immunostaining was performed in whole blood with
speciﬁc ﬂuorochrome-conjugated antibodies (listed in Table 1) at room temperature for 45 min. IL-6R
expression was assessed using a phycoerythrin (PE)-conjugated antibody, which provided the better
resolution in our ﬂow cytometric setting. This was critical to increase the sensitivity of the assay, and
assess quantitative differences in IL-6R expression in different T cell subsets.
Fig. 6. Elevated IL-6R expression delineates a subset of TIGIT mTregs with increased expression of the canonical Th17
markers CD161 and CCR6. (A) Gating strategy to delineate IL-6R/int (depicted in green) and IL-6Rhi (depicted in red) TIGIT
mTregs. (B) Data shown depict the frequencies of the Th17 markers CD161 (N ¼ 23) and CCR6 (N ¼ 12) in IL-6R/int and IL-
6Rhi mTregs, obtained by ﬂow cytometry in freshly isolated PBMCs from healthy donors. P values were calculated using a two-
tailed paired non-parametric Wilcoxon signed rank test.
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Cell sorting was performed using a BD FACSAria Fusion ﬂow cytometer (BD Biosciences) after pre-
enrichment of CD4þ T cells from whole blood by negative selection. Fluorescence-conjugated anti-
bodies used for sorting are described in Table 1. Sorting efﬁciencies were determined in four donors,
based on IL-6R and TIGIT expression and ranged between 90–99%.2.4. Intracellular pSTAT3 immunostainings
PBMCs were isolated from three healthy donors by Ficoll gradient centrifugation fromwhole blood
within 2 h of phlebotomy. IL-6 sensitivity of the memory Treg and Teff subsets was determined by
intracellular pSTAT3 immunostaining in freshly isolated PBMCs in response to IL-6 stimulation
in vitro, as previously described [6].
Fig. 7. ex vivo isolated IL-6RhiTIGITþ mTregs show an activated Treg transcriptional proﬁle. Volcano plot depicts the differential
expression of 579 immune genes in IL-6RhiTIGITþ and IL-6RhiTIGIT mTregs sorted ex vivo from nine independent healthy
donors using NanoString. Plots depicting the normalized read counts from four differentially expressed activated Treg signature
genes (marked in green), HELIOS, HLA-DRA, DUSP4 and FOXP3 are also shown. The ﬂow sorting marker TIGIT, used for the
isolation of the assessed Treg subsets, is marked in black. P values were calculated using two-tailed paired non-parametric
Wilcoxon signed rank tests, comparing the normalized NanoString read counts between IL-6RhiTIGITþ and IL-6RhiTIGIT
mTregs.
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To assess the proliferative capacity of IL-6RhiTIGIT , IL-6RhiTIGITþ and IL-6RloTIGITþ Tregs and
memory Teffs, 104 sorted cells from each subset were labelled with eFluor450 Cell Proliferation Dye
(eBioscience), and cultured in the presence of exogenous IL-2 (100 U/ml; Proleukin) and anti-CD3/
CD28 activation beads, at a 1:1 bead:Teff ratio in X-VIVO 15 þ 5% human AB serum. Cells were
cultured in X-VIVO 15 þ 5% human AB serum for 84 h at 37 °C in V-bottom 96-well cell culture plates
(CELLSTAR, Greiner) in the presence of exogenous IL-2 (100 U/ml; Proleukin) and anti-CD3/CD28
activation beads (Life Technologies), at a 1:1 bead:Teff ratio. Proliferation of the responder cells was
assessed by the dilution of the proliferation dye by ﬂow cytometry.
Proliferation capacity was calculated using the Division Index (DI) in FlowJo (Tree Star). The DI
represents the average number of cell divisions that each seeding Teff cell has undergone and was
obtained using the following equation: DI ¼ Total number of Cell Divisions / Initial number of



























, where n represents the number of divisions and G(n) represents the number
of cells that have undergone n divisions.
Fig. 8. Elevated expression of IL-6R on TIGIT mTregs marks a subset of FOXP3þ RORγtþ TIGIT mTregs. (A) Expression of the
canonical Th17 transcription factor RORγt was assessed on four healthy donors using intracellular ﬂow cytometry. Data shown
depicts the distribution of RORγtþ cells in CD45RA IL-6R/intTIGIT; IL-6RhiTIGIT and TIGITþ CD127lowCD25þ T cells; and in
memory T effector cells (see gating strategy on Fig. 6). The histogram shown depicts an illustrative example of the expression of
RORγt (stratiﬁed by CD45RA) on total CD4þ CD127lowCD25þ T cells. Gating of RORγtþ cells as detected by mAb clone AFKJS-9
followed that of Ayyoub M et al. [4]. (B) Frequency of FOXP3þ cells was assessed within the RORγt and RORγtþ fractions of IL-
6RhiTIGIT mTregs, and in TIGITþ mTregs. Illustrative histogram depicts the co-expression of FOXP3 and RORgt with TIGIT-
CD45RA CD127lowCD25þ T cells. Horizontal bars represent the median distribution of the assessed immune phenotypes in
each group.
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To assess cytokine production, CD4þ T cells were isolated from whole blood by negative selection
using RosetteSep (STEMCELL Technologies) within 2 h of phlebotomy. Cells were resuspended in X-
VIVO 15 (Lonza) þ 5% heat-inactivated, ﬁltered human AB serum (Sigma), and cultured (1–2106
CD4s/well) in a 24-well ﬂat-bottom cell culture plate (CELLSTAR, Greiner) at 37 °C in the presence or
absence of the 1X Cell Stimulation Cocktail (eBiosiences), containing phorbol myristate acetate (PMA),
ionomycin, and protein transport inhibitors (brefeldin A and monensin).
After 6 h culture, cells were harvested and immunostained with surface and intracellular anti-
bodies (listed in Table 1). The unstimulated cells were used to determine background levels of
cytokine production. Dead-cell exclusion was performed using the eFluor780 Fixable Viability Dye
(eBiosciences).
Fig. 9. IL-6RhiTIGITþ mTregs chemokine receptor proﬁle is consistent with a tissue-homing Treg subset. (A) Gating strategy for
the delineation of the Th1, Th2, Th17 and Th22 Treg subsets. The delineation of the Th Treg subsets was based on the deﬁnition
previously described by Duhen et al. [5]. (B) Data shown depicts the frequencies (GeoMean þ/ 95% CI) of the Th subsets in
CD45RA IL-6R /intTIGIT; IL-6RhiTIGIT and TIGITþ CD127lowCD25þ T cells; and in memory T effector cells. (C) Data shown
depicts the frequency of the individual chemokine receptors and cell adhesion markers in the same T cell subsets. P values were
calculated using a two-tailed paired non-parametric Wilcoxon signed rank test, comparing the frequency of the assessed
phenotypes between IL-6RhiTIGIT mTregs and the other T cells subsets. *P o 0.05; **P o 0.01; ***P o 0.001; ****P o 104.
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Fig. 10. IL-6RhiTIGITþ mTregs display the capacity to migrate to the gut. (A,B) Gating strategy for the delineation of the colon-
homing receptors ITGα4þ and ITGα4þβ7þ cells (A) and the small intestine-homing receptor CCR9þ cells (B). Illustrative plots
depict the expression of the assessed gut-homing receptors on CD45RA CD4þ CD127lowCD25þ T cells (C) Data shown depicts
the distribution (median) of ITGα4þ , ITGα4þβ7þ and CCR9þ cells in CD45RA IL-6R/intTIGIT; IL-6RhiTIGIT and TIGITþ
CD127lowCD25þ T cells; and in memory T effector cells.
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Gene expression proﬁling was performed by NanoString, using the pre-designed nCounter Human
Immunology v2 Panel (NanoString Technologies). The four assessed immune cell subsets were ﬂow
sorted as described above, and 25,000 cells were collected into RLT lysis buffer (Qiagen) either:
(i) directly ex vivo; or (ii) following in vitro stimulation for 165 min in the presence or absence of
50 ng/ml PMA (Sigma-Aldrich) and 500 ng/ml ionomycin (Sigma-Aldrich), without addition of pro-
tein transport inhibitors. RNA from the ﬂow-sorted T cell subsets was extracted using the RNAeasy
Micro Plus kit (Qiagen), with gDNA cleanup, following manufacturer's instructions. Total RNA samples
were then hybridized to the NanoString CodeSets, following manufacturer's instructions. Expression
levels were assessed using an nCounter Flex instrument (NanoString Technologies). Data were pro-
cessed using the nSolver Analysis Software following normalization of the raw read counts to the
geometric mean of positive control spike-ins, and the gene expression of 15 selected housekeeping
genes (ATG10, C14orf166, CD3E, CD46, G6PD, GPI, POLR1B, POLR2A, PSMB5, PSMB10, PTPRC, SDHA, SKI,
TOLLIP and TUBB) that were found to have low variability on both the samples collected ex vivo and
following in vitro stimulation.2.8. Statistical analyses
Statistical analyses were performed using Prism software (GraphPad) and R (www.r-project.org.
com). Statistical signiﬁcance was assessed using a two-tailed non-parametric Mann-Whitney test.
Comparison of immune phenotypes between the assessed Treg subsets from the same individual was
performed using a two-tailed paired non-parametric Wilcoxon signed rank test.
Fig. 11. CD45RA TIGITþ memory Tregs produce limited amounts of IL-17 and IL-10 upon in vitro activation. (A,B) Data shown
depict the frequency (GeoMean þ/- 95% CI) of IL-17þ (A) and IL-10þ (B) cells among CD45RATIGITþ mTregs, stratiﬁed by the
expression of HELIOS and FOXP3. IL-17 and IL-10 production was assessed by intracellular ﬂow cytometry in freshly isolated
PBMCs from 10 healthy donors, following in vitro activation with PMA þ ionomycin. (C) Data depict the frequency (GeoMean
þ/ 95% CI) of IL-17 and IL-10 single-producers as well as IL-17/IL-10 double producers among the CD45RATIGITþ Treg
subset.
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paired analysis with DESeq. 2 v1.12.3 [7], with pre-set size factors equal to one for all samples.
Adjusted P values correspond to the false discovery rates (FDR) for differential expression, computed
after correcting P values for multiple testing. A missing FDR is reported for genes that were found to
contain an expression outlier by DESeq. 2 Cook's distance-based ﬂagging of P values, and thus
excluded from multiple testing.
Fig. 12. Single low dose of IL-2 does not preferentially expand CD45RA HELIOSTIGIT mTregs in vivo. (A,B) Data depict the
variation (Mean þ/ SEM) of the frequency of CD45RA HELIOSTIGIT (A) or conventional CD45RA HELIOSþTIGITþ
mTregs (B), following IL-2 treatment in T1D patients receiving: (i) the lower IL-2 doses of 0.04–0.045106 U/ml (N ¼ 2;
depicted in black); or (ii) the higher IL-2 doses of 0.6–1.5 x 106 U/ml (N ¼ 6; depicted in red). Data were obtained from
intracellular staining of cryopreserved PBMCs from eight selected T1D patients enrolled in the “Adaptive study of IL-2 dose on
regulatory T cells in type 1 diabetes” (DILT1D). The DILT1D data from individuals prior to normalization as a group are available,
however they cannot be anonymized sufﬁciently to be able to put into the public domain without risk of participant identi-
ﬁcation. Data are available on request, through the Cambridge University institutional repository (DOI link: https://doi.org/10.
17863/CAM.832).
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Table 1
Antibodies and immunostaining panels used for ﬂow cytometry. Detailed description of the ﬂuorochrome-conjugated anti-
bodies and immunostaining panels used to immunophenotype and ﬂow sort the assessed CD4þ T cell populations.
Immunostaining Panel Antibody Fluorochrome Clone Manufacturer
DILT1D Treg immunophenotyping
(Whole blood)
CD4 AF700 RPA-T4 BioLegend
CD25a APC M-A251þ2A3 BD Biosciences
CD127 PE-Cy7 eBioRDR5 eBioscience
CD45RA BV785 HI100 BioLegend
CD14 PB M5E2 BioLegend
CCR6 AF488 G034E3 BioLegend
IL-6R PE UV4 BioLegend
CD8 APC-Cy7 RPA-T8 BioLegend
CXCR3 PerCP Cy5.5 G025H7 BioLegend
CD62L BV605 DREG-56 BioLegend
IL-6Rhi Treg immunophenotyping
(Freshly isolated PBMCs)
CD3 BV510 UCHT1 BioLegend
CD4 BUV398 SK3 BD Biosciences
CD25a APC M-A251þ2A3 BD Biosciences
CD127 PE-Cy7 eBioRDR5 eBioscience
CD45RA BV785 HI100 BioLegend
CTLA-4 PE-CF594 BNI3 BD Biosciences
CD8 APC-Cy7 RPA-T8 BioLegend
CD62L BV605 DREG-56 BioLegend
PD-1 BV711 EH12.2 BD Biosciences
IL-6R BV421 M5 BD Biosciences
HELIOS FITC 22F6 BioLegend
Ki-67 PerCP Cy5.5 B59 BD Biosciences
FOXP3 PE 259D BioLegend
IL-6RhiTIGIT- Treg immunophenotyping
(Freshly isolated PBMCs)
CD3 BV510 UCHT1 BioLegend
CD4 BUV737 SK3 BD Biosciences
CD25a APC M-A251þ2A3 BD Biosciences
CD127 PE-Cy7 eBioRDR5 eBioscience
CD45RA BV785 HI100 BioLegend
HLA-DR AF700 L243 BioLegend
CD8 APC-Cy7 RPA-T8 BioLegend
CD62L BV605 DREG-56 BioLegend
CCR6 BV711 11A9 BD Biosciences
TIGIT PerCP eFluor710 MBSA43 eBioscience
CD161 PE HP-3G10 BioLegend
IL-6R BV421 M5 BD Biosciences
HELIOS FITC 22F6 BioLegend
Ki-67 BUV398 B59 BD Biosciences
FOXP3 PE-CF594 259D BioLegend
FACS Sorting (Freshly isolated PBMCs) CD3 FITC UCHT1 BioLegend
CD4 AF700 RPA-T4 BioLegend
CD25 APC M-A251 BD Biosciences
CD127 PE-Cy7 eBioRDR5 eBioscience
CD45RA BV785 HI100 BioLegend
IL-6R PE M5 BD Biosciences
TIGIT PerCP eFluor710 MBSA43 eBioscience
Proliferation dye eFluor450 – eBioscience
IL-17/IL-10 production
(Freshly isolated CD4þ T cells)
CD3 BV510 UCHT1 BioLegend
CD4 BUV737 SK3 BD Biosciences
CD25a APC M-A251þ2A3 BD Biosciences
CD127 PE-Cy7 eBioRDR5 eBioscience
CD45RA BV785 HI100 BioLegend
TIGIT PerCP eFluor710 MBSA43 eBioscience
HELIOS FITC 22F6 BioLegend
FOXP3 PE-CF594 259D BioLegend
IL-17 AF700 BL168 BioLegend
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Table 1 (continued )
Immunostaining Panel Antibody Fluorochrome Clone Manufacturer
IC AF700 MOPC-21 BioLegend
IL-10 PE JES-9D7 BioLegend
IC PE RTK2071 BioLegend
Viability Dye eFluor780 – eBioscience
Chemokine receptor proﬁling
(Freshly isolated PBMCs)
CD4 BUV737 SK3 BD Biosciences
CD25a APC M-A251þ2A3 BD Biosciences
CD127 PE-Cy7 eBioRDR5 eBioscience
CD45RA BV785 HI100 BioLegend
TIGIT PerCP eFluor710 MBSA43 eBioscience
CD27 BUV398 L128 BD Biosciences
CD8 APC-Cy7 RPA-T8 BioLegend
IL-6R BV421 M5 BD Biosciences
CCR4 BV510 L291H4 BioLegend
CCR6 AF488 G034E3 BioLegend
CCR10 PE 6588-5 BioLegend
CXCR3 AF700 G025H7 BioLegend
CXCR5 PE-CF594 J252D4 BioLegend
CD15s BV711 CSLEX1 BD Biosciences
RORγt / gut-homing immunophenotyping
(Freshly isolated CD4þ T cells)
CD4 BUV737 SK3 BD Biosciences
CD25a APC M-A251þ2A3 BD Biosciences
CD127 PE-Cy7 eBioRDR5 eBioscience
CD45RA BV785 HI100 BioLegend
TIGIT PerCP eFluor710 MBSA43 eBioscience
CD3 BV510 UCHT1 BioLegend
CCR6 BV711 11A9 BD Biosciences
CD8 APC-Cy7 RPA-T8 BioLegend
IL-6R BV421 M5 BD Biosciences
ITGB7 FITC FIB504 BioLegend
HELIOS FITC 22F6 BioLegend
ITGA4 BV605 9F10 BioLegend
CD62L BV605 DREG-56 BioLegend
CCR9 PE L053E8 BioLegend
RORγ/γt PE AFKJS-9 eBioscience
FOXP3 PE-CF594 259D BioLegend
Ki-67 BUV398 B59 BD Biosciences
a Two clones of anti-CD25 that bind to different epitopes were used simultaneously to enhance CD25 staining. IC, Isotype
control.
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